Athena Wealth Management LLC Purchases Shares of 9,691 AstraZeneca PLC $AZNCF

Athena Wealth Management LLC purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,691 shares of the company’s stock, valued at approximately $1,911,000. AstraZeneca comprises 1.6% of Athena Wealth Management LLC’s investment portfolio, making the stock its 8th biggest position.

A number of other hedge funds have also modified their holdings of AZNCF. Saranac Partners Ltd acquired a new position in shares of AstraZeneca during the 3rd quarter worth approximately $876,000. Mascoma Wealth Management LLC acquired a new stake in AstraZeneca during the 4th quarter valued at $46,000. Valley Wealth Managers Inc. acquired a new stake in AstraZeneca during the 4th quarter valued at $144,000. Hendley & Co. Inc. purchased a new position in AstraZeneca during the fourth quarter worth $11,373,000. Finally, L & S Advisors Inc purchased a new position in AstraZeneca during the fourth quarter worth $14,863,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

OTCMKTS:AZNCF opened at $187.10 on Tuesday. The company’s 50-day moving average is $187.10 and its two-hundred day moving average is $186.10. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.